Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Health Minister Mandaviya inaugurates 27 greenfield bulk drug park, 13 medical device manufacturing plants

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

Pfizer Oncology hosts innovation day

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth

TechInvention Lifecare breaks ground of its GCMC

The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy

Jupiter Life Line Hospitals acquires land in Bibvewadi on lease

Dr Mandaviya addresses WHO’s public launch event of GIDH

Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year

European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose